User login
Practical Neuroscience for Primary Care Physicians: Summer 2007
A supplement to Internal Medicine News.
[[{"attributes":{},"fields":{}}]]
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.
Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.
Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.
Resources in the Spotlight
Practical Bits
Quick and Practical Diagnostic Tools
A supplement to Internal Medicine News.
[[{"attributes":{},"fields":{}}]]
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.
Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.
Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.
Resources in the Spotlight
Practical Bits
Quick and Practical Diagnostic Tools
A supplement to Internal Medicine News.
[[{"attributes":{},"fields":{}}]]
Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.
Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.
Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.
Resources in the Spotlight
Practical Bits
Quick and Practical Diagnostic Tools
Practical Neuroscience for Primary Care Physicians: Spring Issue
A supplement to Internal Medicine News.
TOPIC HIGHLIGHTS/FACULTY
Welcome Letter:
From the Publisher
Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.
Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.
Resources in the Spotlight
Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.
Practical Bits: Diagnostic Tools
A supplement to Internal Medicine News.
TOPIC HIGHLIGHTS/FACULTY
Welcome Letter:
From the Publisher
Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.
Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.
Resources in the Spotlight
Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.
Practical Bits: Diagnostic Tools
A supplement to Internal Medicine News.
TOPIC HIGHLIGHTS/FACULTY
Welcome Letter:
From the Publisher
Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.
Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.
Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.
Resources in the Spotlight
Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.
Practical Bits: Diagnostic Tools
Clinical Update: Challenges in the Management of Constipation and Other Gastrointestinal Disorders
A supplement to Internal Medicine News.
This Clinical Update is supported by Braintree Laboratories, Inc.
The articles are based on interviews with the faculty.
To view the supplement, click the image above.
Topic Highlights
Gastrointestinal Disorders: When to Refer?
Understanding the Anatomy and Physiology of Constipation
Lawrence R. Schiller, MD, FACP, FACG
Program Director, Gastroenterology Fellowship
Department of Gastroenterology
Baylor University Medical Center
Dallas, TX
Consultant: Braintree Laboratories, Inc. and Novartis Pharmaceuticals. He discusses the unlabeled use of tegaserod for constipation. He also discusses the investigational use of NT-3 for constipation.
Management of Constipation Begins With Attention to Clinical Details
Jack A. DiPalma, MD, FACP, FACG
Professor and Director
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile, AL
Grant/Research Support and Consultant: Braintree Laboratories, Inc.
Recent Clinical Trials Provide Stronger Basis for Constipation Therapy
Lawrence R. Schiller, MD, FACP, FACG
Patients at Opposite Ends of the Age Spectrum Share Clinical Features of Constipation
Jack A. DiPalma, MD, FACP, FACG
Surgical Treatment for Chronic Constipation: Favorable Option in Selected Patients
David E. Beck, MD, FACS
Chairman, Department of Colon and Rectal Surgery
Ochsner Clinical Foundation
New Orleans, LA
Nothing to disclose.
Recent H. pylori Literature Explores New Questions
A supplement to Internal Medicine News.
This Clinical Update is supported by Braintree Laboratories, Inc.
The articles are based on interviews with the faculty.
To view the supplement, click the image above.
Topic Highlights
Gastrointestinal Disorders: When to Refer?
Understanding the Anatomy and Physiology of Constipation
Lawrence R. Schiller, MD, FACP, FACG
Program Director, Gastroenterology Fellowship
Department of Gastroenterology
Baylor University Medical Center
Dallas, TX
Consultant: Braintree Laboratories, Inc. and Novartis Pharmaceuticals. He discusses the unlabeled use of tegaserod for constipation. He also discusses the investigational use of NT-3 for constipation.
Management of Constipation Begins With Attention to Clinical Details
Jack A. DiPalma, MD, FACP, FACG
Professor and Director
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile, AL
Grant/Research Support and Consultant: Braintree Laboratories, Inc.
Recent Clinical Trials Provide Stronger Basis for Constipation Therapy
Lawrence R. Schiller, MD, FACP, FACG
Patients at Opposite Ends of the Age Spectrum Share Clinical Features of Constipation
Jack A. DiPalma, MD, FACP, FACG
Surgical Treatment for Chronic Constipation: Favorable Option in Selected Patients
David E. Beck, MD, FACS
Chairman, Department of Colon and Rectal Surgery
Ochsner Clinical Foundation
New Orleans, LA
Nothing to disclose.
Recent H. pylori Literature Explores New Questions
A supplement to Internal Medicine News.
This Clinical Update is supported by Braintree Laboratories, Inc.
The articles are based on interviews with the faculty.
To view the supplement, click the image above.
Topic Highlights
Gastrointestinal Disorders: When to Refer?
Understanding the Anatomy and Physiology of Constipation
Lawrence R. Schiller, MD, FACP, FACG
Program Director, Gastroenterology Fellowship
Department of Gastroenterology
Baylor University Medical Center
Dallas, TX
Consultant: Braintree Laboratories, Inc. and Novartis Pharmaceuticals. He discusses the unlabeled use of tegaserod for constipation. He also discusses the investigational use of NT-3 for constipation.
Management of Constipation Begins With Attention to Clinical Details
Jack A. DiPalma, MD, FACP, FACG
Professor and Director
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile, AL
Grant/Research Support and Consultant: Braintree Laboratories, Inc.
Recent Clinical Trials Provide Stronger Basis for Constipation Therapy
Lawrence R. Schiller, MD, FACP, FACG
Patients at Opposite Ends of the Age Spectrum Share Clinical Features of Constipation
Jack A. DiPalma, MD, FACP, FACG
Surgical Treatment for Chronic Constipation: Favorable Option in Selected Patients
David E. Beck, MD, FACS
Chairman, Department of Colon and Rectal Surgery
Ochsner Clinical Foundation
New Orleans, LA
Nothing to disclose.
Recent H. pylori Literature Explores New Questions
Abuse Potential of Sleeping Agents: Liability Varies Among Agents
A supplement to Internal Medicine News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.
Topic Highlights
• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse
• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis
A supplement to Internal Medicine News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.
Topic Highlights
• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse
• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis
A supplement to Internal Medicine News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.
Topic Highlights
• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse
• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis
New Benchmarks in Acid-Related Disorders: A Debate With the Experts
A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.
To view the supplement, click the image above.
A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.
To view the supplement, click the image above.
A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.
To view the supplement, click the image above.
Improving Survival From Sudden Cardiac Arrest: Is it Time for Home Defibrillators?
A supplement to Internal Medicine News, supported by an unrestricted educational grant from Philips.
Highlights developed from physician interviews and from a panel discussion held in Washington, D.C., on January 30, 2002.
To view the supplement, click the image above.
Richard A. Lazar, Esq.
President/CEO
Fios, Inc.
Portland, Ga.
Nothing to disclose.
A supplement to Internal Medicine News, supported by an unrestricted educational grant from Philips.
Highlights developed from physician interviews and from a panel discussion held in Washington, D.C., on January 30, 2002.
To view the supplement, click the image above.
Richard A. Lazar, Esq.
President/CEO
Fios, Inc.
Portland, Ga.
Nothing to disclose.
A supplement to Internal Medicine News, supported by an unrestricted educational grant from Philips.
Highlights developed from physician interviews and from a panel discussion held in Washington, D.C., on January 30, 2002.
To view the supplement, click the image above.
Richard A. Lazar, Esq.
President/CEO
Fios, Inc.
Portland, Ga.
Nothing to disclose.
Immune Response Modifier Therapy in Anogenital Warts and Actinic Keratoses
A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.
Topic Highlights
• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment
• 3-Year Experience With Imiquimod in Vulvar Warts
• Placebo-Controlled Trial in External Anogenital Warts
• Phase III Trials of Imiquimod in Actinic Keratosis
• Observational Long-Term Study of Imiquimod in Actinic Keratosis
• Immune Response Modifier Mechanism of Action
A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.
Topic Highlights
• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment
• 3-Year Experience With Imiquimod in Vulvar Warts
• Placebo-Controlled Trial in External Anogenital Warts
• Phase III Trials of Imiquimod in Actinic Keratosis
• Observational Long-Term Study of Imiquimod in Actinic Keratosis
• Immune Response Modifier Mechanism of Action
A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.
•Introduction
•Topic Highlights
To view the supplement, click the image above.
Introduction
Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.
Topic Highlights
• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment
• 3-Year Experience With Imiquimod in Vulvar Warts
• Placebo-Controlled Trial in External Anogenital Warts
• Phase III Trials of Imiquimod in Actinic Keratosis
• Observational Long-Term Study of Imiquimod in Actinic Keratosis
• Immune Response Modifier Mechanism of Action
Shift-work disorder
The burden of shift-work disorder (SWD) is multifactorial—affecting relationships, health, and work performance. Lack of support, research, and treatment for SWD has economic and safety consequences for society in general. In this supplement, sleep experts suggest practical steps to relieve the adverse effects of SWD.
The burden of shift-work disorder (SWD) is multifactorial—affecting relationships, health, and work performance. Lack of support, research, and treatment for SWD has economic and safety consequences for society in general. In this supplement, sleep experts suggest practical steps to relieve the adverse effects of SWD.
The burden of shift-work disorder (SWD) is multifactorial—affecting relationships, health, and work performance. Lack of support, research, and treatment for SWD has economic and safety consequences for society in general. In this supplement, sleep experts suggest practical steps to relieve the adverse effects of SWD.
Support
Support for the publication of this supplement was provided by Cephalon, Inc. Editorial assistance was provided by Anthemis Consulting Ltd and supported by Cephalon, Inc.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily represent those of Cephalon, Inc., or the publishers. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested by the authors should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparisons with the recommendations of other authorities. Content may include product information that is inconsistent with or outside the approved labeling for these products in the United States. Before prescribing any medication, you must familiarize yourself with the manufacturer’s product information.
This material was submitted by Anthemis Consulting Ltd on behalf of the authors. It has been edited and peer reviewed by The Journal of Family Practice.
Managing Acid-Related Disorders Through the Ages of Mankind
A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on October 22, 2002, in Seattle, Wash.
To view the supplement, click the image above.
A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on October 22, 2002, in Seattle, Wash.
To view the supplement, click the image above.
A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on October 22, 2002, in Seattle, Wash.
To view the supplement, click the image above.
